BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23032887)

  • 1. Risk of second cancers after photon and proton radiotherapy: a review of the data.
    Yock TI; Caruso PA
    Health Phys; 2012 Nov; 103(5):577-85. PubMed ID: 23032887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of second malignancies among patients treated with proton versus photon radiation.
    Chung CS; Yock TI; Nelson K; Xu Y; Keating NL; Tarbell NJ
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):46-52. PubMed ID: 23778197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsequent malignancies after photon versus proton radiation therapy.
    Bekelman JE; Schultheiss T; Berrington De Gonzalez A
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):10-2. PubMed ID: 23810521
    [No Abstract]   [Full Text] [Related]  

  • 4. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.
    Tubiana M
    Radiother Oncol; 2009 Apr; 91(1):4-15; discussion 1-3. PubMed ID: 19201045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling recurrence and second cancer risks induced by proton therapy.
    Manem VSK; Dhawan A
    Math Med Biol; 2018 Sep; 35(3):347-361. PubMed ID: 29106564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.
    Simone CB; Kramer K; O'Meara WP; Bekelman JE; Belard A; McDonough J; O'Connell J
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):242-9. PubMed ID: 21236595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric CSI: are protons the only ethical approach?
    Johnstone PA; McMullen KP; Buchsbaum JC; Douglas JG; Helft P
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):228-30. PubMed ID: 23958143
    [No Abstract]   [Full Text] [Related]  

  • 8. [The issue of low doses in radiation therapy and impact on radiation-induced secondary malignancies].
    Chargari C; Cosset JM
    Bull Cancer; 2013 Dec; 100(12):1333-42. PubMed ID: 24257106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation.
    Schneider U; Lomax A; Lombriser N
    Radiat Res; 2000 Oct; 154(4):382-8. PubMed ID: 11023601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton therapy in the management of lymphoma.
    Ho CK; Flampouri S; Hoppe BS
    Cancer J; 2014; 20(6):387-92. PubMed ID: 25415683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing second breast cancers: a potential role for prophylactic mammary irradiation.
    Brenner DJ; Shuryak I; Russo S; Sachs RK
    J Clin Oncol; 2007 Nov; 25(31):4868-72. PubMed ID: 17971581
    [No Abstract]   [Full Text] [Related]  

  • 12. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma.
    Arvold ND; Niemierko A; Broussard GP; Adams J; Fullerton B; Loeffler JS; Shih HA
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e495-500. PubMed ID: 22285662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative treatment planning using secondary cancer mortality calculations.
    Schneider U; Lomax A; Lombriser N
    Phys Med; 2001; 17 Suppl 1():97-9. PubMed ID: 11770547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiation therapy, protons, and the risk of second cancers.
    Hall EJ
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):1-7. PubMed ID: 16618572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
    Glanzmann C; Veraguth A; Lütolf UM
    Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma.
    Brodin NP; Munck Af Rosenschöld P; Aznar MC; Kiil-Berthelsen A; Vogelius IR; Nilsson P; Lannering B; Björk-Eriksson T
    Acta Oncol; 2011 Aug; 50(6):806-16. PubMed ID: 21767178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.
    Bairati I; Meyer F; Gélinas M; Fortin A; Nabid A; Brochet F; Mercier JP; Têtu B; Harel F; Mâsse B; Vigneault E; Vass S; del Vecchio P; Roy J
    J Natl Cancer Inst; 2005 Apr; 97(7):481-8. PubMed ID: 15812073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
    van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
    Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out-of-field neutron and leakage photon exposures and the associated risk of second cancers in high-energy photon radiotherapy: current status.
    Takam R; Bezak E; Marcu LG; Yeoh E
    Radiat Res; 2011 Oct; 176(4):508-20. PubMed ID: 21756083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.